Celgene Prices $1.5 Bln Of

(RTTNews) - Celgene Corp. (CELG) said Friday that it has priced three series of senior unsecured notes for an aggregate principal amount of $1,500 million.

Of those notes, $400 million will mature in 2018 and will bear interest at an annual rate of 2.300%; $700 million will mature in 2023 and will bear interest at an annual rate of 4.000% and $400 million will mature in 2043 and will bear interest at an annual rate of 5.250%. The 2.300% notes due 2018, the 4.000% notes due 2023 and the 5.250% notes due in 2043 were priced to yield 2.344%, 4.067% and 5.307%, respectively.

The offering is expected to close on August 6.

Celgene expects to use the net proceeds from the offering for general corporate purposes, which may include, without limitation, further development of the company's clinical and pre-clinical programs, capital expenditures, general corporate development activities, meeting working capital needs, share repurchases of Celgene's common stock and repayment of some or all of Celgene's outstanding commercial paper.